Merck Sharp Dohme Ltd
11 products tracked · names used in filings: Merck Sharp Dohme Ltd, Merck Sharp Dohme Ltd., Merck Sharp Dohme Limited
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Wed 15 Apr 2026🇪🇺 EU approval (EC decision)
Enflonsia (clesrovimab) approved in the EU
Marketing authorisation to Merck Sharp Dohme Limited; Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Janacti | Application withdrawn | |
| 🇪🇺 | Vorinostat MSD vorinostat | Application withdrawn | |
| 🇪🇺 | Enflonsia clesrovimab | Authorised | 2026-04-15 |
| 🇪🇺 | Dutrebis lamivudine;raltegravir potassium | Withdrawn | 2015-03-26 |
| 🇪🇺 | Zontivity vorapaxar | Withdrawn | 2015-01-19 |
| 🇪🇺 | Victrelis boceprevir | Withdrawn | 2011-07-18 |
| 🇪🇺 | Tredaptive laropiprant;nicotinic acid | Withdrawn | 2008-07-03 |
| 🇪🇺 | Trevaclyn laropiprant;nicotinic acid | Withdrawn | 2008-07-03 |
| 🇪🇺 | Pelzont laropiprant;nicotinic acid | Withdrawn | 2008-07-03 |
| 🇪🇺 | Silgard human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) | Withdrawn | 2006-09-19 |
| 🇪🇺 | ViraferonPeg peginterferon alfa-2b | Withdrawn | 2000-05-28 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.